Advertisement
Advertisement
OCUL
Ocular Therapeutix, Inc.
8.20
USDSponsored
-0.13
-1.62%
Mar 26, 13:46 UTC -4
Open
OCUL Earnings Reports
Positive Surprise Ratio
OCUL beat 19 of 41 last estimates.
46%
Next Report
Date of Next Report
May 04, 2026
Estimate for Q1 26 (Revenue/ EPS)
$12.68M
/-$0.32
Implied change from Q4 25 (Revenue/ EPS)
-4.28%
/+14.29%
Implied change from Q1 25 (Revenue/ EPS)
+18.55%
/-15.79%
Ocular Therapeutix, Inc. earnings per share and revenue
On Feb 05, 2026, OCUL reported earnings of -0.28 USD per share (EPS) for Q4 25, beating the estimate of -0.33 USD, resulting in a 12.73% surprise. Revenue reached 13.25 million, compared to an expected 16.45 million, with a -19.46% difference. The market reacted with a +4.21% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 9 analysts forecast an EPS of -0.32 USD, with revenue projected to reach 12.68 million USD, implying an increase of 14.29% EPS, and decrease of -4.28% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Theravance Biopharma, Inc.
Report Date
Mar 19, 2026 For Q4 25
Estimate
$1.24
Actual
$0.21
Surprise
-83.12%
Context Therapeutics Inc. Common Stock
Report Date
Mar 23, 2026 For Q4 25
Estimate
-$0.10
Actual
-$0.14
Surprise
-29.39%
Avalo Therapeutics, Inc. Common Stock
Report Date
Mar 23, 2026 For Q4 25
Estimate
-$1.49
Actual
-$1.12
Surprise
+24.33%
Journey Medical Corporation Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.05
Actual
-$0.04
Surprise
+31.86%
Surrozen, Inc. Common
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$1.21
Actual
-Surprise
-
Achieve Life Sciences, Inc.
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.27
Actual
-$0.28
Surprise
-1.12%
Pyxis Oncology, Inc. Common Stock
Report Date
Mar 23, 2026 For Q4 25
Estimate
-$0.34
Actual
-$0.28
Surprise
+15.55%
Acrivon Therapeutics, Inc. Common Stock
Report Date
Mar 19, 2026 For Q4 25
Estimate
-$0.47
Actual
-$0.52
Surprise
-9.34%
Fractyl Health, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.18
Actual
$0.15
Surprise
+181.70%
NRX Pharmaceuticals, Inc. Common Stock
Report Date
Mar 23, 2026 For Q4 25
Estimate
$0.00
Actual
-$0.01
Surprise
-361.54%
FAQ
What were Ocular Therapeutix, Inc.'s earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Ocular Therapeutix, Inc. reported EPS of -$0.28, beating estimates by 12.73%, and revenue of $13.25M, -19.46% below expectations.
How did the market react to Ocular Therapeutix, Inc.'s Q4 2025 earnings?
The stock price moved up 4.21%, changed from $8.55 before the earnings release to $8.91 the day after.
When is Ocular Therapeutix, Inc. expected to report next?
The next earning report is scheduled for May 04, 2026.
What are the forecasts for Ocular Therapeutix, Inc.'s next earnings report?
Based on 9
analysts, Ocular Therapeutix, Inc. is expected to report EPS of -$0.32 and revenue of $12.68M for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement